Teleflex completes patient enrollment for European coronary scaffold study
Teleflex Incorporated has enrolled 102 patients in a European trial testing longer dissolvable magnesium scaffolds to treat extensive coronary artery disease.
FTMQ Health, written by our newsroom0 views
Teleflex Incorporated has finished enrolling 102 human patients in a European clinical study evaluating longer versions of its dissolvable magnesium coronary scaffold. MyChesCo reported that the trial focuses on patients with extensive coronary artery disease. [1]
According to MyChesCo, the BIOMAG-LL study took place across 14 European medical centers. Researchers are assessing the safety and clinical performance of 35-millimeter and 40-millimeter versions of the Freesolve Resorbable Magnesium Scaffold on previously untreated coronary artery lesions. [1]
A bioresorbable stent is a tube-like medical device placed in clogged heart arteries to restore blood flow. Unlike traditional metal options, it dissolves into the body over time, releases medication to reduce scar tissue, and helps restore normal blood vessel function. [2]
The trial aims to advance research into dissolvable magnesium scaffolds as a possible alternative to permanent metal stents for complex heart conditions, MyChesCo reported. [1]
In short
- Teleflex enrolled 102 patients across 14 European medical centers for the BIOMAG-LL study.
- The trial evaluates 35-millimeter and 40-millimeter dissolvable magnesium scaffolds.
- Bioresorbable scaffolds dissolve into the body and release drugs to limit scar tissue growth.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Teleflex Completes Enrollment in Coronary Scaffold TrialMyChesCo, 5h ago (the report this story comes from)
Background
- [2]Bioresorbable stent on Wikipedia
Our newsroom writes these reports with the help of software, from the 2 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Ear nerve stimulation shows promise for severe high blood pressureFitness, 1d ago
- UK clinical trial tests repurposed diabetes and ADHD drugs for Alzheimer diseaseTop Stories, 4d ago
- Ebola drug trial launches in Congo as death toll exceeds four thousandMedical Science, 21d ago
- Henry Ford Health Begins Trial for Pulmonary Artery Denervation TreatmentMedical Science, 2d ago
- Modest weight loss in middle age improves cardiovascular health, study findsTop Stories, 5d ago
More in Medical Science
- Missing blood pressure medication reduces cardiovascular protection study shows2h ago
- Experts urge structured cardiac screening to prevent sudden deaths in youth2d ago
- Henry Ford Health Begins Trial for Pulmonary Artery Denervation Treatment2d ago
- MsFLASH clinical trials network findings remain key guide for menopause care2d ago
- Fortrea and Omico partner to match Australian cancer patients with clinical trials3d ago
- Researchers publish framework to improve outcome definitions in clinical trials4d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.
Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.